Regeneron Pharmaceuticals, Inc.
0
0
0%

Financials

Income statement

Fundamentals currency is USD
Fiscal date Sep 2025 Jun 2025 Mar 2025 Dec 2024
Total reported revenue 3.2B 3.1B 2.6B 3.2B
Cost of revenue 444.7M 452.0M 395.8M 482.0M
Gross profit 2.8B 2.7B 2.2B 2.7B
Operating expense
Research & development 1.3B 1.2B 1.1B 1.2B
Selling general and admin 560.8M 540.6M 539.6M 675.3M
Other operating expenses -8.5M 13.2M
Operating income 946.2M 920.3M 504.4M 844.1M
Non operating interest income
Income 149.3M 149.0M 147.9M 156.1M
Expense 16.5M 3.1M 7.4M 9.0M
Other income expense 424.2M 228.5M 126.6M -174.5M
Pretax income 1.5B 1.3B 771.5M 816.8M
Tax provision 258.6M 108.4M 82.1M 34.4M
Net income 1.2B 1.2B 689.4M 782.3M
Basic EPS 13.2 7.6 8.5
Diluted EPS 12.8 7.3 8.1
Basic average shares 89.6M 91.0M 91.7M
Diluted average shares 92.6M 94.8M 97.0M
EBITDA 1.2B 1.2B 768.0M 1.1B
Net income from continuing op. 1.2B 1.2B 689.4M 782.3M
Minority interests
Preferred stock dividends
Access the full /income_statement historical dataset via the API — starting from the Pro plan.
Market closed

Exchange is currently closed
Pre-market opens in 4 hours 24 minutes

03:35
00:00
08:55
17:35
23:59

Trading Hours (Monday - Friday):

Pre-market
08:00 - 08:55
Main market
08:55 - 17:35
Post-market
17:35 - 17:50
All times are displayed in the Europe/Vienna timezone (CET, UTC+01:00).